We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $520K invested in Avenue Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

30% more funds holding

Funds holding: 10 → 13 (+3)

32% less capital invested

Capital invested by funds: $766K → $520K (-$246K)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$638K
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$129K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$115K
4
VF
Virtu Financial
New York
+$78.7K
5
Citigroup
Citigroup
New York
+$40.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$362K
2
Two Sigma Investments
Two Sigma Investments
New York
-$145K
3
TSS
Two Sigma Securities
New York
-$143K
4
TRCT
Tower Research Capital (TRC)
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$306K +$638K +3,520 New
Bank of New York Mellon
2
Bank of New York Mellon
New York
$61.9K +$129K +712 New
Qube Research & Technologies (QRT)
3
Qube Research & Technologies (QRT)
United Kingdom
$55K +$115K +632 New
VF
4
Virtu Financial
New York
$38K +$78.7K +434 New
Citigroup
5
Citigroup
New York
$20.1K +$40.6K +224 +3,200%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$13K +$27.9K +154 New
BCM
7
Bayesian Capital Management
New York
$12.8K +$26.7K +147 New
Wells Fargo
8
Wells Fargo
California
$5.29K – – –
Morgan Stanley
9
Morgan Stanley
New York
$3.87K +$4.35K +24 +120%
BlackRock
10
BlackRock
New York
$2.25K – – –
UBS Group
11
UBS Group
Switzerland
$1.45K +$363 +2 +13%
EL
12
EMFO LLC
Florida
$618 – – –
Bank of America
13
Bank of America
North Carolina
$14 – – –
Citadel Advisors
14
Citadel Advisors
Florida
– -$362K -478 Closed
Two Sigma Investments
15
Two Sigma Investments
New York
– -$145K -191 Closed
TSS
16
Two Sigma Securities
New York
– -$143K -189 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$14K -19 Closed
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
– +$181 +1 New

ATXI Hedge Fund Activity: Q4 2022 in Review

13 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2022, worth a combined $520K — down 32% from $766K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ATXI positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $638K. The largest seller was Citadel Advisors, exiting entirely with an estimated $362K sold.

  • 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2022, up from 10 in Q3 2022.
  • Funds reported $520K of Avenue Therapeutics, Inc. Common Stock stock for Q4 2022, down 32% quarter-over-quarter.
  • 7 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2022 and 4 closed out, a net change of +3 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2022 was Sabby Management, an estimated $638K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $362K sold.

Based on aggregated 13F filings for Q4 2022.